Spero Therapeutics, Inc.
News
Spero Therapeutics to Present at Upcoming September Investor Conferences
Globe Newswire CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...\n more…
Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript
Seeking Alpha: Transcripts Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript...\n more…
SPRO Stock Earnings: Spero Therapeutics Beats EPS, Beats Revenue for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nSPRO stock results show that Spero Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter...\n more…
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
Zacks Investment Research Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.23 per share a year ago. These...\n more…
Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update
Globe Newswire Enrollment concluded in the Phase 2a proof-of-concept clinical trial evaluating SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); preliminary data expected in 4Q 2024New SPR720...\n more…
Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024
Globe Newswire CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...\n more…